The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

The United States said Tuesday it has delivered a new treatment to prevent HIV in two African countries, months after President Donald Trump dramatically cut global aid.

The US has started to provide doses of a Gilead HIV prevention drug to low-income countries, but the program will not include ...

The Pennsylvania Department of Health will cut 25% of funding to the Part B of the Ryan White HIV/AIDS Program amid rising ...

Tennessee Gov. Bill Lee said the state had applied for a federal grant funding for rural healthcare, hoping for a piece of ...

The MarketWatch News Department was not involved in the creation of this content. SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pluristyx, Inc., a leading biotechnology company specializing in tools and ...

Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to reduce the severity of infections such as bird flu, and cure HIV and other ...

Gilead Sciences, Inc.’s GILD posted 3% year-over-year growth in total revenues for the third quarter of 2025. Total revenues comprise product sales and royalty, contract and other revenues. While ...

Our researchers have worked at the forefront of HIV care, research, education, and policy since the earliest stages of the epidemic. We conduct basic, translational, and implementation research here ...